The ins and outs of nanoparticle technology in neurodegenerative diseases and cancer

Current Drug Metabolism

Volumn 16, Issue 8, 2015, Pages 609-632

  Wilson, Cornelia M ^a   Magnaudeix, Amandine ^a   Naves, Thomas ^a   Vincent, François ^a,b   Lalloué, Fabrice ^a   Jauberteau, Marie Odile ^a  

^a UNIVERSITÉ DE LIMOGES   (France)

^b LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

Alzheimer's disease; Cancer; Nanoparticle; Nanovesicle; Neurodegenerative diseases; Therapy

Indexed keywords

CARBON NANOTUBE; CERIUM OXIDE NANOPARTICLE; DENDRIMER; GOLD NANOPARTICLE; HYDROXYAPATITE; MESOPOROUS SILICA NANOPARTICLE; NANO HYDROXYAPATITE; NANOGEL; NANOPARTICLE; POLYMER; QUANTUM DOT; SOLID LIPID NANOPARTICLE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ALTERNATIVE MEDICINE; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BLOOD BRAIN BARRIER; CANCER THERAPY; DEGENERATIVE DISEASE; DRUG DELIVERY SYSTEM; EXOSOME; GENE THERAPY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NANOMEDICINE; NANOTECHNOLOGY; NEUROLOGIC DISEASE; PARKINSON DISEASE; ANIMAL; NEOPLASMS; NEURODEGENERATIVE DISEASES;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; NEURODEGENERATIVE DISEASES;

EID: 84947936284     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200216666150812121902     Document Type: Article

References (317)

1. Nie, Z.; Petukhova, A.; Kumacheva, E. Properties and emerging applications of self-assembled structures made from inorganic nanoparticles. Nat. Nanotechnol., 2010, 5(1), 15-25.
2. Davis, M. E.; Chen, Z. G.; Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov., 2008, 7(9), 771-82.
3. Adiseshaiah, P. P.; Hall, J. B.; McNeil, S. E. Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2010, 2(1), 99-112.
4. Gastaldi, L.; Battaglia, L.; Peira, E.; Chirio, D.; Muntoni, E.; Solazzi, I.; Gallarate, M.; Dosio, F. Solid lipid nanoparticles as vehicles of drugs to the brain: Current state of the art. Eur. J. Pharm. Biopharm., 2014, 87(3), 433-444.
5. Muller, R. H.; Maassen, S.; Weyhers, H.; Mehnert, W. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J. Drug Target., 1996, 4(3), 161-70.
6. zur Muhlen, A.; Schwarz, C.; Mehnert, W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur. J. Pharm. Biopharm., 1998, 45(2), 149-55.
7. ™) dispersions. Int. J. Pharm., 1998, 168, 221-229.
8. Ekambaram, P.; Abdul, H. S. Formulation and evaluation of solid lipid nanoparticles of ramipril. J. Young Pharm., 2011, 3(3), 216-20.
9. Ammon, H. P.; Wahl, M. A. Pharmacology of Curcuma longa. Planta medica, 1991, 57(1), 1-7.
10. Aggarwal, B. B.; Harikumar, K. B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol., 2009, 41(1), 40-59.
11. Kakkar, V.; Singh, S.; Singla, D.; Kaur, I. P. Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Mol. Nutr. Food Res., 2011, 55(3), 495-503.
12. Torchilin, V. P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov., 2005, 4(2), 145-60.
13. Bangham, A. D.; Standish, M. M.; Watkins, J. C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol., 1965, 13(1), 238-52.
14. Couvreur, P. Polyalkylcyanoacrylates as colloidal drug carriers. Crit. Rev. Ther. Drug Carrier Syst., 1988, 5(1), 1-20.
15. Duncan, R. The dawning era of polymer therapeutics. Nature reviews. Drug Discov., 2003, 2(5), 347-60.
16. Faraday, M. Experimental relations of gold (and other metals) to light. Philos. Trans. R. Soc. Lond., 1857, 147, 145-181.
17. Wagner, F. E.; Haslbeck, S.; Stievano, L.; Calogero, S.; Pankhurst, Q. A.; Martinek, K. P. Before striking gold in gold-ruby glass. Nature, 2000, 407(6805), 691-2.
18. Edwards, P. P.; Thomas, J. M. Gold in a metallic divided state-from Faraday to present-day nanoscience. Angew. Chem., 2007, 46(29), 5480-6.
19. Sperling, R. A.; Rivera Gil, P.; Zhang, F.; Zanella, M.; Parak, W. J. Biological applications of gold nanoparticles. Chem. Soc. Rev., 2008, 37(9), 1896-908.
20. Rossetti, R.; Nakahara, S.; Brus, L. E. Quantum size effects in the redox potentials, resonance Raman spectra, and electronic spectra of CdS crystallites in aqueous solution. J. Chem. Phys., 1983, 79, 1086-1088.
21. de Mello Donega, C. Synthesis and properties of colloidal heteronanocrystals. Chem. Soc. Rev., 2011, 40(3), 1512-46.
22. Alivisatos, A. P.; Gu, W.; Larabell, C. Quantum dots as cellular probes. Annu. Rev. Biomed. Eng., 2005, 7, 55-76.
23. Algar, W. R.; Susumu, K.; Delehanty, J. B.; Medintz, I. L. Semiconductor quantum dots in bioanalysis: crossing the valley of death. Anal. Chem., 2011, 83(23), 8826-37.
24. He, X.; Ma, N. An overview of recent advance of quantum dots for biomedical applications. Colloids Surf. B Biointerfaces, 2014.
25. Iijima, S. Helical microtubules of graphitic carbon. Nature, 1991, 354(6348), 56-58.
26. Elhissi, A. M.; Ahmed, W.; Hassan, I. U.; Dhanak, V. R.; D'Emanuele, A. Carbon nanotubes in cancer therapy and drug delivery. J. Drug Deliv., 2012, 2012, 837327.
27. De Volder, M. F.; Tawfick, S. H.; Baughman, R. H.; Hart, A. J. Carbon nanotubes: present and future commercial applications. Science, 2013, 339(6119), 535-9.
28. Chen, J.; Chen, S.; Zhao, X.; Kuznetsova, L. V.; Wong, S. S.; Ojima, I. Functionalized single-walled carbon nanotubes as rationally designed vehicles for tumor-targeted drug delivery. J. Am. Chem. Soc., 2008, 130(49), 16778-85.
29. Ji, Z.; Lin, G.; Lu, Q.; Meng, L.; Shen, X.; Dong, L.; Fu, C.; Zhang, X. Targeted therapy of SMMC-7721 liver cancer in vitro and in vivo with carbon nanotubes based drug delivery system. J. Colloid Interface Sci., 2012, 365(1), 143-9.
30. Hampel, S.; Kunze, D.; Haase, D.; Kramer, K.; Rauschenbach, M.; Ritschel, M.; Leonhardt, A.; Thomas, J.; Oswald, S.; Hoffmann, V.; Buchner, B. Carbon nanotubes filled with a chemotherapeutic agent: a nanocarrier mediates inhibition of tumor cell growth. Nanomedicine, 2008, 3(2), 175-82.
31. Adeli, M.; Soleyman, R.; Beiranvand, Z.; Madani, F. Carbon nanotubes in cancer therapy: a more precise look at the role of carbon nanotube-polymer interactions. Chem. Soc. Rev., 2013, 42(12), 5231-56.
32. Kaminskas, L. M.; McLeod, V. M.; Porter, C. J.; Boyd, B. J. Association of chemotherapeutic drugs with dendrimer nanocarriers: an assessment of the merits of covalent conjugation compared to noncovalent encapsulation. Mol. Pharm., 2012, 9(3), 355-73.
33. De, M.; Ghosh, P. S.; Rotello, V. M. Applications of Nanoparticles in Biology. Adv. Mater., 2008, 20(22), 4225-4241.
34. Jun, Y.-w.; Lee, J.-H.; Cheon, J. Chemical Design of Nanoparticle Probes for High-Performance Magnetic Resonance Imaging. Angew. Chem. Int. Ed., 2008, 47(28), 5122-5135.
35. Laurent, S.; Forge, D.; Port, M.; Roch, A.; Robic, C.; Vander Elst, L.; Muller, R. N. Magnetic Iron Oxide Nanoparticles: Synthesis, Stabilization, Vectorization, Physicochemical Characterizations, and Biological Applications. Chem. Rev., 2008, 108(6), 2064-2110.
36. Corma, A.; Atienzar, P.; Garcia, H.; Chane-Ching, J.-Y. Hierarchically mesostructured doped CeO2 with potential for solar-cell use. Nat. Mater., 2004, 3(6), 394-397.
37. Patil, S.; Kuiry, S. C.; Seal, S.; Vanfleet, R. Synthesis of Nanocrystalline Ceria Particles for High Temperature Oxidation Resistant Coating. J. Nanopart. Res., 2002, 4(5), 433-438.
38. Stambouli, A. B.; Traversa, E. Solid oxide fuel cells (SOFCs): a review of an environmentally clean and efficient source of energy. Renew. Sust. Energy Rev., 2002, 6(5), 433-455.
39. 2-based oxides
40. Celardo, I.; Pedersen, J. Z.; Traversa, E.; Ghibelli, L. Pharmacological potential of cerium oxide nanoparticles. Nanoscale, 2011, 3(4), 1411-1420.
41. Pirmohamed, T.; Dowding, J. M.; Singh, S.; Wasserman, B.; Heckert, E.; Karakoti, A. S.; King, J. E.; Seal, S.; Self, W. T. Nanoceria exhibit redox state-dependent catalase mimetic activity. Chem. Commun. (Camb)., 2010, 46(16), 2736-8.
42. Korsvik, C.; Patil, S.; Seal, S.; Self, W. T. Superoxide dismutase mimetic properties exhibited by vacancy engineered ceria nanoparticles. Chem. Commun. (Camb)., 2007, (10), 1056-8.
43. Xue, Y.; Luan, Q.; Yang, D.; Yao, X.; Zhou, K. Direct Evidence for Hydroxyl Radical Scavenging Activity of Cerium Oxide Nanoparticles. J. Phys. Chem. C, 2011, 115(11), 4433-4438.
44. Dowding, J. M.; Dosani, T.; Kumar, A.; Seal, S.; Self, W. T. Cerium oxide nanoparticles scavenge nitric oxide radical (NO). Chem. Commun. (Camb)., 2012, 48(40), 4896-8.
45. Asati, A.; Santra, S.; Kaittanis, C.; Nath, S.; Perez, J. M. Oxidaselike activity of polymer-coated cerium oxide nanoparticles. Angew. Chem., 2009, 48(13), 2308-12.
46. Asati, A.; Santra, S.; Kaittanis, C.; Perez, J. M. Surface-chargedependent cell localization and cytotoxicity of cerium oxide nanoparticles. ACS Nano, 2010, 4(9), 5321-31.
47. Wason, M. S.; Colon, J.; Das, S.; Seal, S.; Turkson, J.; Zhao, J.; Baker, C. H. Sensitization of pancreatic cancer cells to radiation by cerium oxide nanoparticle-induced ROS production. Nanomedicine, 2013, 9(4), 558-69.
48. Siefker, J.; Karande, P.; Coppens, M. O. Packaging biological cargoes in mesoporous materials: opportunities for drug delivery. Expert Opin. Drug Deliv., 2014, 1-13.
49. Tasciotti, E.; Liu, X.; Bhavane, R.; Plant, K.; Leonard, A. D.; Price, B. K.; Cheng, M. M.; Decuzzi, P.; Tour, J. M.; Robertson, F.; Ferrari, M. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat. Nanotechnol., 2008, 3(3), 151-7.
50. Serda, R. E.; Godin, B.; Blanco, E.; Chiappini, C.; Ferrari, M. Multi-stage delivery nano-particle systems for therapeutic applications. Biochim. Biophys. Acta, 2011, 1810(3), 317-29.
51. van den Bergh, J. P.; van Geel, T. A.; Geusens, P. P. Osteoporosis, frailty and fracture: implications for case finding and therapy. Nat. Rev. Rheumatol., 2012, 8(3), 163-72.
52. Wu, G. J.; Zhou, L. Z.; Wang, K. W.; Chen, F.; Sun, Y.; Duan, Y. R.; Zhu, Y. J.; Gu, H. C. Hydroxylapatite nanorods: an efficient and promising carrier for gene transfection. J. Colloid Interface Sci., 2010, 345(2), 427-32.
53. Epple, M.; Ganesan, K.; Heumann, R.; Klesing, J.; Kovtun, A.; Neumann, S.; Sokolova, V. Application of calcium phosphate nanoparticles in biomedicine. J. Mater. Chem., 2010, 20(1), 18-23.
54. Chu, S. H.; Feng, D. F.; Ma, Y. B.; Li, Z. Q. Hydroxyapatite nanoparticles inhibit the growth of human glioma cells in vitro and in vivo. Int. J. Nanomed., 2012, 7, 3659-66.
55. Kundu, B.; Ghosh, D.; Sinha, M. K.; Sen, P. S.; Balla, V. K.; Das, N.; Basu, D. Doxorubicin-intercalated nano-hydroxyapatite drugdelivery system for liver cancer: An animal model. Ceram. Int., 2013, 39(8), 9557-9566.
56. Kabanov, A. V.; Vinogradov, S. V. Nanogels as pharmaceutical carriers: finite networks of infinite capabilities. Angew. Chem., 2009, 48(30), 5418-29.
57. Lee, H.; Mok, H.; Lee, S.; Oh, Y. K.; Park, T. G. Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels. J. Control. Release, 2007, 119(2), 245-52.
58. Kumar, M.; Kakkar, V.; Mishra, A. K.; Chuttani, K.; Kaur, I. P. Intranasal delivery of streptomycin sulfate (STRS) loaded solid lipid nanoparticles to brain and blood. Int. J. Pharm., 2014, 461(1-2), 223-33.
59. Uner, M.; Yener, G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int. J. Nanomedicine, 2007, 2(3), 289-300.
60. Patel, A.; Cholkar, K.; Mitra, A. K. Recent developments in protein and peptide parenteral delivery approaches. Ther. Deliv., 2014, 5(3), 337-65.
61. Bakhru, S. H.; Furtado, S.; Morello, A. P.; Mathiowitz, E. Oral delivery of proteins by biodegradable nanoparticles. Adv. Drug Deliv. Rev., 2013, 65(6), 811-21.
62. Schmidt, C.; Lautenschlaeger, C.; Collnot, E. M.; Schumann, M.; Bojarski, C.; Schulzke, J. D.; Lehr, C. M.; Stallmach, A. Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: a first in vivo study in human patients. J. Control. Release, 2013, 165(2), 139-45.
63. Vyas, A.; Kumar Sonker, A.; Gidwani, B. Carrier-based drug delivery system for treatment of acne. Scientific World J., 2014, 2014, 276260.
64. Andrade, F.; Rafael, D.; Videira, M.; Ferreira, D.; Sosnik, A.; Sarmento, B. Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases. Adv. Drug Deliv. Rev., 2013, 65(13-14), 1816-27.
65. Willis, L.; Hayes, D. Jr.; Mansour, H. M. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. Lung, 2012, 190(3), 251-62.
66. Lochhead, J. J.; Thorne, R. G. Intranasal delivery of biologics to the central nervous system. Adv. Drug Deliv. Rev., 2012, 64(7), 614-28.
67. Illum, L. Nasal drug delivery - recent developments and future prospects. J. Control. Release, 2012, 161(2), 254-63.
68. Liu, S.; Jones, L.; Gu, F. X. Nanomaterials for ocular drug delivery. Macromol. Biosci., 2012, 12(5), 608-20.
69. Kozlovskaya, L.; Abou-Kaoud, M.; Stepensky, D. Quantitative analysis of drug delivery to the brain via nasal route. J. Control. Release, 2014, 189 c, 133-140.
70. Damge, C.; Socha, M.; Ubrich, N.; Maincent, P. Poly (epsiloncaprolactone)/eudragit nanoparticles for oral delivery of aspartinsulin in the treatment of diabetes. J. Pharm. Sci., 2010, 99(2), 879-89.
71. Coco, R.; Plapied, L.; Pourcelle, V.; Jerome, C.; Brayden, D. J.; Schneider, Y. J.; Preat, V. Drug delivery to inflamed colon by nanoparticles: comparison of different strategies. Int. J. Pharm., 2013, 440(1), 3-12.
72. Hosseininasab, S.; Pashaei-Asl, R.; Khandaghi, A. A.; Nasrabadi, H. T.; Nejati-Koshki, K.; Akbarzadeh, A.; Joo, S. W.; Hanifehpour, Y.; Davaran, S. Synthesis, Characterization, and In vitro Studies of PLGA-PEG Nanoparticles for Oral Insulin Delivery. Chem. Biol. Drug Des., 2014, 84(3), 307-15.
73. Mitra, R. N.; Merwin, M. J.; Han, Z.; Conley, S. M.; Al-Ubaidi, M. R.; Naash, M. I. Yttrium oxide nanoparticles prevent photoreceptor death in a light-damage model of retinal degeneration. Free Radiac. Biol. Med., 2014.
74. Yang, H.; Tyagi, P.; Kadam, R. S.; Holden, C. A.; Kompella, U. B. Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration. ACS nano, 2012, 6(9), 7595-606.
75. Youshia, J.; Kamel, A. O.; El Shamy, A.; Mansour, S. Design of cationic nanostructured heterolipid matrices for ocular delivery of methazolamide. Int. J. Nanomed., 2012, 7, 2483-96.
76. Giannavola, C.; Bucolo, C.; Maltese, A.; Paolino, D.; Vandelli, M. A.; Puglisi, G.; Lee, V. H.; Fresta, M. Influence of preparation conditions on acyclovir-loaded poly-d, l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharm. Res., 2003, 20(4), 584-90.
77. Kalita, D.; Shome, D.; Jain, V. G.; Chadha, K.; Bellare, J. R. In vivo intraocular distribution and safety of periocular nanoparticle carboplatin for treatment of advanced retinoblastoma in humans. Am. J. Ophthalmol., 2014, 157(5), 1109-15.
78. Santos, I. S.; Ponte, B. M.; Boonme, P.; Silva, A. M.; Souto, E. B. Nanoencapsulation of polyphenols for protective effect against colonrectal cancer. Biotechnol. Adv., 2013, 31(5), 514-23.
79. Mohamed, R. A.; Abass, H. A.; Attia, M. A.; Heikal, O. A. Formulation and evaluation of metoclopramide solid lipid nanoparticles for rectal suppository. J. Pharm. Pharmacol., 2013, 65(11), 1607-21.
80. Roy, S.; Johnston, A. H.; Newman, T. A.; Glueckert, R.; Dudas, J.; Bitsche, M.; Corbacella, E.; Rieger, G.; Martini, A.; Schrott-Fischer, A. Cell-specific targeting in the mouse inner ear using nanoparticles conjugated with a neurotrophin-derived peptide ligand: potential tool for drug delivery. Int. J. Pharm., 2010, 390(2), 214-24.
81. Raber, A. S.; Mittal, A.; Schafer, J.; Bakowsky, U.; Reichrath, J.; Vogt, T.; Schaefer, U. F.; Hansen, S.; Lehr, C. M. Quantification of nanoparticle uptake into hair follicles in pig ear and human forearm. J. Control. Release, 2014, 179, 25-32.
82. Groo, A. C.; Saulnier, P.; Gimel, J. C.; Gravier, J.; Ailhas, C.; Benoit, J. P.; Lagarce, F. Fate of paclitaxel lipid nanocapsules in intestinal mucus in view of their oral delivery. Int. J. Nanomed., 2013, 8, 4291-302.
83. Yang, M.; Lai, S. K.; Yu, T.; Wang, Y. Y.; Happe, C.; Zhong, W.; Zhang, M.; Anonuevo, A.; Fridley, C.; Hung, A.; Fu, J.; Hanes, J. Nanoparticle penetration of human cervicovaginal mucus: The effect of polyvinyl alcohol. J. Control. Release, 2014, 192 c, 202-208.
84. Frohlich, E.; Roblegg, E. Mucus as barrier for drug delivery by nanoparticles. J. Nanosci. Nanotechnol., 2014, 14(1), 126-36.
85. Bhatta, R. S.; Chandasana, H.; Chhonker, Y. S.; Rathi, C.; Kumar, D.; Mitra, K.; Shukla, P. K. Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: In vitro and pharmacokinetics studies. Int. J. Pharm., 2012, 432(1-2), 105-12.
86. Mazzarino, L.; Travelet, C.; Ortega-Murillo, S.; Otsuka, I.; Pignot-Paintrand, I.; Lemos-Senna, E.; Borsali, R. Elaboration of chitosancoated nanoparticles loaded with curcumin for mucoadhesive applications. J. Colloid Interface Sci., 2012, 370(1), 58-66.
87. Leonardi, A.; Bucolo, C.; Romano, G. L.; Platania, C. B.; Drago, F.; Puglisi, G.; Pignatello, R. Influence of different surfactants on the technological properties and in vivo ocular tolerability of lipid nanoparticles. Int. J. Pharm., 2014, 470(1-2), 133-40.
88. Holden, C. A.; Tyagi, P.; Thakur, A.; Kadam, R.; Jadhav, G.; Kompella, U. B.; Yang, H. Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs. Nanomedicine, 2012, 8(5), 776-83.
89. Veldhorst-Janssen, N. M.; Fiddelers, A. A.; van der Kuy, P. H.; Neef, C.; Marcus, M. A. A review of the clinical pharmacokinetics of opioids, benzodiazepines, and antimigraine drugs delivered intranasally. Clin. Ther., 2009, 31(12), 2954-87.
90. Sznitowska, M.; Gajewska, M.; Janicki, S.; Radwanska, A.; Lukowski, G., Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. Eur. J. Pharm. Biopharm., 2001, 52(2), 159-63.
91. Shakya, P.; Madhav, N. V.; Shakya, A. K.; Singh, K. Palatal mucosa as a route for systemic drug delivery: A review. J. Control. Release, 2011, 151(1), 2-9.
92. Mura, S.; Nicolas, J.; Couvreur, P. Stimuli-responsive nanocarriers for drug delivery. Nat. Mater., 2013, 12(11), 991-1003.
93. Kourtis, I. C.; Hirosue, S.; de Titta, A.; Kontos, S.; Stegmann, T.; Hubbell, J. A.; Swartz, M. A. Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. PloS one, 2013, 8(4), e61646.
94. Etame, A. B.; Diaz, R. J.; O'Reilly, M. A.; Smith, C. A.; Mainprize, T. G.; Hynynen, K.; Rutka, J. T. Enhanced delivery of gold nanoparticles with therapeutic potential into the brain using MRIguided focused ultrasound. Nanomedicine, 2012, 8(7), 1133-42.
95. Diaz, R. J.; McVeigh, P. Z.; O'Reilly, M. A.; Burrell, K.; Bebenek, M.; Smith, C.; Etame, A. B.; Zadeh, G.; Hynynen, K.; Wilson, B. C.; Rutka, J. T. Focused ultrasound delivery of Raman nanoparticles across the blood-brain barrier: potential for targeting experimental brain tumors. Nanomedicine, 2014, 10(5), 1075-87.
96. Ferri, C. P.; Prince, M.; Brayne, C.; Brodaty, H.; Fratiglioni, L.; Ganguli, M.; Hall, K.; Hasegawa, K.; Hendrie, H.; Huang, Y.; Jorm, A.; Mathers, C.; Menezes, P. R.; Rimmer, E.; Scazufca, M. Global prevalence of dementia: a Delphi consensus study. Lancet, 2005, 366(9503), 2112-7.
97. Reitz, C.; Mayeux, R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem. Pharmacol., 2014, 88(4), 640-51.
98. Prakash, K. M.; Tan, E. K. Development of Parkinson's disease biomarkers. Expert Rev. Neurother., 2010, 10(12), 1811-25.
99. Bieschke, J. Natural compounds may open new routes to treatment of amyloid diseases. Neurotherapeutics, 2013, 10(3), 429-39.
100. Guo, J. L.; Lee, V. M. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat. Med., 2014, 20(2), 130-8.
101. Renner, M.; Melki, R. Protein aggregation and prionopathies. Pathol. Biol. (Paris), 2014, 62(3), 162-8.
102. Kopito, R. R. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol., 2000, 10(12), 524-30.
103. Huang, Y.; Mucke, L. Alzheimer mechanisms and therapeutic strategies. Cell, 2012, 148(6), 1204-22.
104. Komatsu, M.; Kominami, E. Autophagic-lysosomal system: physiology and pathology. Nihon shinkei seishin yakurigaku zasshi, 2006, 26(2), 75-81.
105. Speakman, J. R.; Mitchell, S. E. Caloric restriction. Mol. Aspects Med., 2011, 32(3), 159-221.
106. Ross, C. A.; Poirier, M. A. Protein aggregation and neurodegenerative disease. Nat. Med., 2004, 10 Suppl, S10-7.
107. Bosco, D. A.; Morfini, G.; Karabacak, N. M.; Song, Y.; Gros-Louis, F.; Pasinelli, P.; Goolsby, H.; Fontaine, B. A.; Lemay, N.; McKenna-Yasek, D.; Frosch, M. P.; Agar, J. N.; Julien, J. P.; Brady, S. T.; Brown, R. H. Jr. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat. Neurosci., 2010, 13(11), 1396-403.
108. Martin, L.; Latypova, X.; Terro, F. Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochem. Int., 2011, 58(4), 458-71.
109. Balch, W. E.; Morimoto, R. I.; Dillin, A.; Kelly, J. W. Adapting proteostasis for disease intervention. Science, 2008, 319(5865), 916-9.
110. Morimoto, R. I. Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging. Genes Dev., 2008, 22(11), 1427-38.
111. Tyedmers, J.; Mogk, A.; Bukau, B. Cellular strategies for controlling protein aggregation. Nat. Rev. Mol. Cell Biol., 2010, 11(11), 777-88.
112. Haigis, M. C.; Yankner, B. A. The aging stress response. Mol. Cell, 2010, 40(2), 333-44.
113. Hipp, M. S.; Park, S. H.; Hartl, F. U. Proteostasis impairment in protein-misfolding and -aggregation diseases. Trends Cell Biol., 2014.
114. Kroemer, G.; Marino, G.; Levine, B. Autophagy and the integrated stress response. Mol. Cell, 2010, 40(2), 280-93.
115. Hutt, D. M.; Powers, E. T.; Balch, W. E. The proteostasis boundary in misfolding diseases of membrane traffic. FEBS Lett., 2009, 583(16), 2639-46.
116. Powers, E. T.; Morimoto, R. I.; Dillin, A.; Kelly, J. W.; Balch, W. E. Biological and chemical approaches to diseases of proteostasis deficiency. Annu. Rev. Biochem., 2009, 78, 959-91.
117. Dubois, B.; Feldman, H. H.; Jacova, C.; Dekosky, S. T.; Barberger-Gateau, P.; Cummings, J.; Delacourte, A.; Galasko, D.; Gauthier, S.; Jicha, G.; Meguro, K.; O'Brien, J.; Pasquier, F.; Robert, P.; Rossor, M.; Salloway, S.; Stern, Y.; Visser, P. J.; Scheltens, P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol., 2007, 6(8), 734-46.
118. Amieva, H.; Jacqmin-Gadda, H.; Orgogozo, J. M.; Le Carret, N.; Helmer, C.; Letenneur, L.; Barberger-Gateau, P.; Fabrigoule, C.; Dartigues, J. F. The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain, 2005, 128(Pt 5), 1093-101.
119. Barnes, D. E.; Yaffe, K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol., 2011, 10(9), 819-28.
120. Obeso, J. A.; Rodriguez-Oroz, M. C.; Goetz, C. G.; Marin, C.; Kordower, J. H.; Rodriguez, M.; Hirsch, E. C.; Farrer, M.; Schapira, A. H.; Halliday, G. Missing pieces in the Parkinson's disease puzzle. Nature Med., 2010, 16(6), 653-61.
121. Majoor-Krakauer, D.; Willems, P. J.; Hofman, A. Genetic epidemiology of amyotrophic lateral sclerosis. Clin. Genet., 2003, 63(2), 83-101.
122. Golde, T. E.; Borchelt, D. R.; Giasson, B. I.; Lewis, J. Thinking laterally about neurodegenerative proteinopathies. J. Clin. Invest., 2013, 123(5), 1847-55.
123. Hawkins, B. T.; Davis, T. P. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev., 2005, 57(2), 173-85.
124. Abbott, N. J.; Ronnback, L.; Hansson, E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci., 2006, 7(1), 41-53.
125. Pardridge, W. M. CNS drug design based on principles of bloodbrain barrier transport. J. Neurochem., 1998, 70(5), 1781-92.
126. Ballabh, P.; Braun, A.; Nedergaard, M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis., 2004, 16(1), 1-13.
127. Wohlfart, S.; Gelperina, S.; Kreuter, J. Transport of drugs across the blood-brain barrier by nanoparticles. J. Control. Release, 2012, 161(2), 264-73.
128. Stockwell, J.; Abdi, N.; Lu, X.; Maheshwari, O.; Taghibiglou, C. Novel central nervous system drug delivery systems. Chem. Biol. Drug Des., 2014, 83(5), 507-20.
129. Kreuter, J.; Alyautdin, R. N.; Kharkevich, D. A.; Ivanov, A. A. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res., 1995, 674(1), 171-4.
130. Spuch, C.; Saida, O.; Navarro, C. Advances in the treatment of neurodegenerative disorders employing nanoparticles. Recent Pat. Drug Deliv. Formul., 2012, 6(1), 2-18.
131. Mathis, C. A.; Klunk, W. E.; Price, J. C.; DeKosky, S. T. Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. Arch. Neurol., 2005, 62(2), 196-200.
132. Jack, C. R.; Wiste, H. J.; Knopman, D. S.; Vemuri, P.; Mielke, M. M.; Weigand, S. D.; Senjem, M. L.; Gunter, J. L.; Lowe, V.; Gregg, B. E.; Pankratz, V. S.; Petersen, R. C. Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration. Neurology, 2014, 82(18), 1605-1612.
133. Villemagne, V. L.; Pike, K. E.; Chetelat, G.; Ellis, K. A.; Mulligan, R. S.; Bourgeat, P.; Ackermann, U.; Jones, G.; Szoeke, C.; Salvado, O.; Martins, R.; O'Keefe, G.; Mathis, C. A.; Klunk, W. E.; Ames, D.; Masters, C. L.; Rowe, C. C. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann. Neur., 2011, 69(1), 181-92.
134. Aizenstein, H. J.; Nebes, R. D.; Saxton, J. A.; Price, J. C.; Mathis, C. A.; Tsopelas, N. D.; Ziolko, S. K.; James, J. A.; Snitz, B. E.; Houck, P. R.; Bi, W.; Cohen, A. D.; Lopresti, B. J.; DeKosky, S. T.; Halligan, E. M.; Klunk, W. E. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol., 2008, 65(11), 1509-17.
135. Spires-Jones, T. L.; Stoothoff, W. H.; de Calignon, A.; Jones, P. B.; Hyman, B. T. Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci., 2009, 32(3), 150-9.
136. Pehlivan, S. B. Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases. Pharm. Res., 2013, 30(10), 2499-511.
137. Jaruszewski, K. M.; Curran, G. L.; Swaminathan, S. K.; Rosenberg, J. T.; Grant, S. C.; Ramakrishnan, S.; Lowe, V. J.; Poduslo, J. F.; Kandimalla, K. K. Multimodal nanoprobes to target cerebrovascular amyloid in Alzheimer's disease brain. Biomaterials, 2014, 35(6), 1967-76.
138. Agasti, S. S.; Rana, S.; Park, M. H.; Kim, C. K.; You, C. C.; Rotello, V. M. Nanoparticles for detection and diagnosis. Adv. Drug Deliv. Rev., 2010, 62(3), 316-28.
139. Agyare, E. K.; Jaruszewski, K. M.; Curran, G. L.; Rosenberg, J. T.; Grant, S. C.; Lowe, V. J.; Ramakrishnan, S.; Paravastu, A. K.; Poduslo, J. F.; Kandimalla, K. K. Engineering theranostic nanovehicles capable of targeting cerebrovascular amyloid deposits. J. Control. Release, 2014, 185, 121-9.
140. Prades, R.; Guerrero, S.; Araya, E.; Molina, C.; Salas, E.; Zurita, E.; Selva, J.; Egea, G.; Lopez-Iglesias, C.; Teixido, M.; Kogan, M. J.; Giralt, E. Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor. Biomaterials, 2012, 33(29), 7194-205.
141. Salvati, E.; Re, F.; Sesana, S.; Cambianica, I.; Sancini, G.; Masserini, M.; Gregori, M. Liposomes functionalized to overcome the blood-brain barrier and to target amyloid-beta peptide: the chemical design affects the permeability across an in vitro model. Int. J. Nanomedicine, 2013, 8, 1749-58.
142. Gabathuler, R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol. Dis., 2010, 37(1), 48-57.
143. Moghimi, S. M. Bionanotechnologies for treatment and diagnosis of Alzheimer's disease. Nanomedicine, 2011, 7(5), 515-8.
144. Silva, G. A. Nanotechnology approaches to crossing the bloodbrain barrier and drug delivery to the CNS. BMC Neurosci., 2008, 9 Suppl 3, S4.
145. Liu, Y. Y.; Yang, X. Y.; Li, Z.; Liu, Z. L.; Cheng, D.; Wang, Y.; Wen, X. J.; Hu, J. Y.; Liu, J.; Wang, L. M.; Wang, H. J. Characterization of polyethylene glycol-polyethyleneimine as a vector for alpha-synuclein siRNA delivery to PC12 cells for Parkinson's disease. CNS Neurosci. Ther., 2014, 20(1), 76-85.
146. Li, S.; Liu, Z.; Ji, F.; Xiao, Z.; Wang, M.; Peng, Y.; Zhang, Y.; Liu, L.; Liang, Z.; Li, F. Delivery of Quantum Dot-siRNA Nanoplexes in SK-N-SH Cells for BACE1 Gene Silencing and Intracellular Imaging. Mol. Ther. Nucleic acids, 2012, 1, e20.
147. Goedert, M.; Spillantini, M. G. A century of Alzheimer's disease. Science (New York, N. Y.), 2006, 314(5800), 777-81.
148. Spires-Jones, T. L.; Kopeikina, K. J.; Koffie, R. M.; de Calignon, A.; Hyman, B. T. Are tangles as toxic as they look? J. Mol. Neurosci., 2011, 45(3), 438-44.
149. Tokuraku, K.; Marquardt, M.; Ikezu, T. Real-time imaging and quantification of amyloid-beta peptide aggregates by novel quantumdot nanoprobes. PloS one, 2009, 4(12), e8492.
150. Skaat, H.; Corem-Slakmon, E.; Grinberg, I.; Last, D.; Goez, D.; Mardor, Y.; Margel, S. Antibody-conjugated, dual-modal, nearinfrared fluorescent iron oxide nanoparticles for antiamyloidgenic activity and specific detection of amyloid-beta fibrils. Int. J. Nanomed., 2013, 8, 4063-76.
151. Ishigaki, Y.; Tanaka, H.; Akama, H.; Ogara, T.; Uwai, K.; Tokuraku, K. A microliter-scale high-throughput screening system with quantum-dot nanoprobes for amyloid-beta aggregation inhibitors. PloS one, 2013, 8(8), e72992.
152. Medina-Sanchez, M.; Miserere, S.; Morales-Narvaez, E.; Merkoci, A. On-chip magneto-immunoassay for Alzheimer's biomarker electrochemical detection by using quantum dots as labels. Biosens. Bioelectron., 2014, 54, 279-84.
153. Stegurova, L.; Draberova, E.; Bartos, A.; Draber, P.; Ripova, D.; Draber, P. Gold nanoparticle-based immuno-PCR for detection of tau protein in cerebrospinal fluid. J. Immunol. Methods, 2014, 406, 137-42.
154. Boyer, C.; Whittaker, M. R.; Bulmus, V.; Liu, J.; Davis, T. P. The design and utility of polymer-stabilized iron-oxide nanoparticles for nanomedicine applications. NPG Asia Mater., 2010, 2, 23-30.
155. Zhou, J.; Fa, H.; Yin, W.; Zhang, J.; Hou, C.; Huo, D.; Zhang, D.; Zhang, H. Synthesis of superparamagnetic iron oxide nanoparticles coated with a DDNP-carboxyl derivative for in vitro magnetic resonance imaging of Alzheimer's disease. Mater. Sci. Eng. C Mater. Biol. Appl., 2014, 37, 348-55.
156. Yang, J.; Wadghiri, Y. Z.; Hoang, D. M.; Tsui, W.; Sun, Y.; Chung, E.; Li, Y.; Wang, A.; de Leon, M.; Wisniewski, T. Detection of amyloid plaques targeted by USPIO-Abeta1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging. NeuroImage, 2011, 55(4), 1600-9.
157. Sillerud, L. O.; Solberg, N. O.; Chamberlain, R.; Orlando, R. A.; Heidrich, J. E.; Brown, D. C.; Brady, C. I.; Vander Jagt, T. A.; Garwood, M.; Vander Jagt, D. L. SPION-enhanced magnetic resonance imaging of Alzheimer's disease plaques in AbetaPP/PS-1 transgenic mouse brain. J. Alzheimers Dis., 2013, 34(2), 349-65.
158. Wadghiri, Y. Z.; Li, J.; Wang, J.; Hoang, D. M.; Sun, Y.; Xu, H.; Tsui, W.; Li, Y.; Boutajangout, A.; Wang, A.; de Leon, M.; Wisniewski, T. Detection of amyloid plaques targeted by bifunctional USPIO in Alzheimer's disease transgenic mice using magnetic resonance microimaging. PloS one, 2013, 8(2), e57097.
159. Beckmann, N.; Gerard, C.; Abramowski, D.; Cannet, C.; Staufenbiel, M. Noninvasive magnetic resonance imaging detection of cerebral amyloid angiopathy-related microvascular alterations using superparamagnetic iron oxide particles in APP transgenic mouse models of Alzheimer's disease: application to passive Abeta immunotherapy. J. Neurosci., 2011, 31(3), 1023-31.
160. Brambilla, D.; Verpillot, R.; Le Droumaguet, B.; Nicolas, J.; Taverna, M.; Kona, J.; Lettiero, B.; Hashemi, S. H.; De Kimpe, L.; Canovi, M.; Gobbi, M.; Nicolas, V.; Scheper, W.; Moghimi, S. M.; Tvaroska, I.; Couvreur, P.; Andrieux, K. PEGylated nanoparticles bind to and alter amyloid-beta peptide conformation: toward engineering of functional nanomedicines for Alzheimer's disease. ACS nano, 2012, 6(7), 5897-908.
161. Amiri, H.; Saeidi, K.; Borhani, P.; Manafirad, A.; Ghavami, M.; Zerbi, V. Alzheimer's disease: pathophysiology and applications of magnetic nanoparticles as MRI theranostic agents. ACS Chem. Neurosci., 2013, 4(11), 1417-29.
162. Ehrnhoefer, D. E.; Bieschke, J.; Boeddrich, A.; Herbst, M.; Masino, L.; Lurz, R.; Engemann, S.; Pastore, A.; Wanker, E. E. EGCG redirects amyloidogenic polypeptides into unstructured, offpathway oligomers. Nat. Struct. Mol. Biol., 2008, 15(6), 558-66.
163. Lopez del Amo, J. M.; Fink, U.; Dasari, M.; Grelle, G.; Wanker, E. E.; Bieschke, J.; Reif, B. Structural properties of EGCG-induced, nontoxic Alzheimer's disease Abeta oligomers. J. Mol. Biol., 2012, 421(4-5), 517-24.
164. Zhang, J.; Zhou, X.; Yu, Q.; Yang, L.; Sun, D.; Zhou, Y.; Liu, J. Epigallocatechin-3-gallate (EGCG)-stabilized selenium nanoparticles coated with Tet-1 peptide to reduce amyloid-beta aggregation and cytotoxicity. ACS Appl. Mater. Interfaces, 2014, 6(11), 8475-87.
165. Bereczki, E.; Re, F.; Masserini, M. E.; Winblad, B.; Pei, J. J. Liposomes functionalized with acidic lipids rescue Abeta-induced toxicity in murine neuroblastoma cells. Nanomedicine, 2011, 7(5), 560-71.
166. Beevers, C. S.; Chen, L.; Liu, L.; Luo, Y.; Webster, N. J.; Huang, S. Curcumin disrupts the Mammalian target of rapamycin-raptor complex. Cancer Res., 2009, 69(3), 1000-8.
167. Han, J.; Pan, X. Y.; Xu, Y.; Xiao, Y.; An, Y.; Tie, L.; Pan, Y.; Li, X. J. Curcumin induces autophagy to protect vascular endothelial cell survival from oxidative stress damage. Autophagy, 2012, 8(5), 812-25.
168. Alavez, S.; Vantipalli, M. C.; Zucker, D. J.; Klang, I. M.; Lithgow, G. J. Amyloid-binding compounds maintain protein homeostasis
169. Gao, H.; Pang, Z.; Jiang, X. Targeted delivery of nano-therapeutics for major disorders of the central nervous system. Pharm. Res., 2013, 30(10), 2485-98.
170. Wilson, C. M.; Magnaudeix, A.; Yardin, C.; Terro, F. Autophagy dysfunction and its link to Alzheimer's disease and type II diabetes mellitus. CNS Neurol. Disord. Drug Targets, 2014, 13(2), 226-46.
171. Lazar, A. N.; Mourtas, S.; Youssef, I.; Parizot, C.; Dauphin, A.; Delatour, B.; Antimisiaris, S. G.; Duyckaerts, C. Curcuminconjugated nanoliposomes with high affinity for Abeta deposits: possible applications to Alzheimer disease. Nanomedicine, 2013, 9(5), 712-21.
172. Mourtas, S.; Canovi, M.; Zona, C.; Aurilia, D.; Niarakis, A.; La Ferla, B.; Salmona, M.; Nicotra, F.; Gobbi, M.; Antimisiaris, S. G. Curcumin-decorated nanoliposomes with very high affinity for amyloid-beta1-42 peptide. Biomaterials, 2011, 32(6), 1635-45.
173. Mourtas, S.; Lazar, A. N.; Markoutsa, E.; Duyckaerts, C.; Antimisiaris, S. G. Multifunctional nanoliposomes with curcumin-lipid derivative and brain targeting functionality with potential applications for Alzheimer disease. Eur. J. Med. Chem., 2014, 80, 175-83.
174. Cheng, K. K.; Yeung, C. F.; Ho, S. W.; Chow, S. F.; Chow, A. H.; Baum, L. Highly stabilized curcumin nanoparticles tested in an in vitro blood-brain barrier model and in Alzheimer's disease Tg2576 mice. AAPS J., 2013, 15(2), 324-36.
175. Tiwari, S. K.; Agarwal, S.; Seth, B.; Yadav, A.; Nair, S.; Bhatnagar, P.; Karmakar, M.; Kumari, M.; Chauhan, L. K.; Patel, D. K.; Srivastava, V.; Singh, D.; Gupta, S. K.; Tripathi, A.; Chaturvedi, R. K.; Gupta, K. C. Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer's disease model via canonical Wnt/beta-catenin pathway. ACS nano, 2014, 8(1), 76-103.
176. Baysal, I.; Yabanoglu-Ciftci, S.; Tunc-Sarisozen, Y.; Ulubayram, K.; Ucar, G. Interaction of selegiline-loaded PLGA-b-PEG nanoparticles with beta-amyloid fibrils. J. Neural. Transm. (Vienna), 2013, 120(6), 903-10.
177. Swomley, A. M.; Forster, S.; Keeney, J. T.; Triplett, J.; Zhang, Z.; Sultana, R.; Butterfield, D. A. Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies. Biochim. Biophys. Acta, 2014, 1842(8), 1248-57.
178. Sarpietro, M. G.; Accolla, M. L.; Puglisi, G.; Castelli, F.; Montenegro, L. Idebenone loaded solid lipid nanoparticles: calorimetric studies on surfactant and drug loading effects. Int. J. Pharm., 2014, 471(1-2), 69-74.
179. Mizrahi, M.; Friedman-Levi, Y.; Larush, L.; Frid, K.; Binyamin, O.; Dori, D.; Fainstein, N.; Ovadia, H.; Ben-Hur, T.; Magdassi, S.; Gabizon, R. Pomegranate seed oil nanoemulsions for the prevention and treatment of neurodegenerative diseases: the case of genetic CJD. Nanomedicine, 2014, 10(6), 1353-63.
180. Massoud, F.; Gauthier, S. Update on the pharmacological treatment of Alzheimer's disease. Curr. Neuropharmacol., 2010, 8(1), 69-80.
181. Andrieux, K.; Couvreur, P. Nanomedicine as a promising approach for the treatment and diagnosis of brain diseases: the example of Alzheimer's disease. Ann. Pharm. Fr., 2013, 71(4), 225-33.
182. Yang, Z. Z.; Zhang, Y. Q.; Wang, Z. Z.; Wu, K.; Lou, J. N.; Qi, X. R. Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration. Int. J. Pharm., 2013, 452(1-2), 344-54.
183. Ismail, M. F.; Elmeshad, A. N.; Salem, N. A. Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer's disease. Int. J. Nanomed., 2013, 8, 393-406.
184. Pagar, K. P.; Sardar, S. M.; Vavia, P. R. Novel L-lactidedepsipeptide polymeric carrier for enhanced brain uptake of rivastigmine in treatment of Alzheimer's disease. J. Biomed. Nanotechnol., 2014, 10(3), 415-26.
185. Mufamadi, M. S.; Choonara, Y. E.; Kumar, P.; Modi, G.; Naidoo, D.; van Vuuren, S.; Ndesendo, V. M.; Toit, L. C.; Iyuke, S. E.; Pillay, V. Ligand-functionalized nanoliposomes for targeted delivery of galantamine. Int. J. Pharm., 2013, 448(1), 267-81.
186. Pundir, S.; Chauhan, N.; Narang, J.; Pundir, C. S. Amperometric choline biosensor based on multiwalled carbon nanotubes/zirconium oxide nanoparticles electrodeposited on glassy carbon electrode. Anal. Biochem., 2012, 427(1), 26-32.
187. Rossi, L.; Squitti, R.; Pasqualetti, P.; Marchese, E.; Cassetta, E.; Forastiere, E.; Rotilio, G.; Rossini, P. M.; Finazzi-Agro, A. Red blood cell copper, zinc superoxide dismutase activity is higher in Alzheimer's disease and is decreased by D-penicillamine. Neurosci. Lett., 2002, 329(2), 137-40.
188. Noda, Y.; Asada, M.; Kubota, M.; Maesako, M.; Watanabe, K.; Uemura, M.; Kihara, T.; Shimohama, S.; Takahashi, R.; Kinoshita, A.; Uemura, K. Copper enhances APP dimerization and promotes Abeta production. Neurosci. Lett., 2013, 547, 10-5.
189. Strozyk, D.; Launer, L. J.; Adlard, P. A.; Cherny, R. A.; Tsatsanis, A.; Volitakis, I.; Blennow, K.; Petrovitch, H.; White, L. R.; Bush, A. I. Zinc and copper modulate Alzheimer Abeta levels in human cerebrospinal fluid. Neurobiol. Aging, 2009, 30(7), 1069-77.
190. Chen, W. T.; Liao, Y. H.; Yu, H. M.; Cheng, I. H.; Chen, Y. R. Distinct effects of Zn2+, Cu2+, Fe3+, and Al3+ on amyloid-beta stability, oligomerization, and aggregation: amyloid-beta destabiliduring zation promotes annular protofibril formation. J. Biol. Chem., 2011, 286(11), 9646-56.
191. Cui, Z.; Lockman, P. R.; Atwood, C. S.; Hsu, C. H.; Gupte, A.; Allen, D. D.; Mumper, R. J. Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. Eur. J. Pharm. Biopharm., 2005, 59(2), 263-72.
192. Bandopadhyay, R.; de Belleroche, J. Pathogenesis of Parkinson's disease: emerging role of molecular chaperones. Trends Mol. Med., 2010, 16(1), 27-36.
193. Garbayo, E.; Ansorena, E.; Blanco-Prieto, M. J. Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems. Maturitas, 2013, 76(3), 272-8.
194. Deng, H.; Yuan, L. Genetic variants and animal models in SNCA and Parkinson disease. Ageing Res. Rev., 2014, 15, 161-76.
195. Tiwari, M. N.; Agarwal, S.; Bhatnagar, P.; Singhal, N. K.; Tiwari, S. K.; Kumar, P.; Chauhan, L. K.; Patel, D. K.; Chaturvedi, R. K.; Singh, M. P.; Gupta, K. C. Nicotine-encapsulated poly (lactic-coglycolic) acid nanoparticles improve neuroprotective efficacy against MPTP-induced parkinsonism. Free Radic. Biol. Med., 2013, 65, 704-18.
196. Meissner, W. G.; Frasier, M.; Gasser, T.; Goetz, C. G.; Lozano, A.; Piccini, P.; Obeso, J. A.; Rascol, O.; Schapira, A.; Voon, V.; Weiner, D. M.; Tison, F.; Bezard, E. Priorities in Parkinson's disease research. Nat. Rev. Drug Discov., 2011, 10(5), 377-93.
197. De Giglio, E.; Trapani, A.; Cafagna, D.; Sabbatini, L.; Cometa, S. Dopamine-loaded chitosan nanoparticles: formulation and analytical characterization. Anal. Bioanal. Chem., 2011, 400(7), 1997-2002.
198. Trapani, A.; De Giglio, E.; Cafagna, D.; Denora, N.; Agrimi, G.; Cassano, T.; Gaetani, S.; Cuomo, V.; Trapani, G. Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery. Int. J. Pharm., 2011, 419(1-2), 296-307.
199. Pillay, S.; Pillay, V.; Choonara, Y. E.; Naidoo, D.; Khan, R. A.; du Toit, L. C.; Ndesendo, V. M.; Modi, G.; Danckwerts, M. P.; Iyuke, S. E. Design, biometric simulation and optimization of a nanoenabled scaffold device for enhanced delivery of dopamine to the brain. Int. J. Pharm., 2009, 382(1-2), 277-90.
200. Md, S.; Haque, S.; Fazil, M.; Kumar, M.; Baboota, S.; Sahni, J. K.; Ali, J. Optimised nanoformulation of bromocriptine for direct nosetobrain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method. Expert Opin. Drug Deliv., 2014, 11(6), 827-42.
201. Magen, I.; Hornstein, E. Oligonucleotide-based therapy for neurodegenerative diseases. Brain Res., 2014.
202. Vinogradov, S. V.; Batrakova, E. V.; Kabanov, A. V. Nanogels for oligonucleotide delivery to the brain. Bioconjugate Chem., 2004, 15(1), 50-60.
203. Cheng, L.; Quek, C. Y.; Sun, X.; Bellingham, S. A.; Hill, A. F. The detection of microRNA associated with Alzheimer's disease in biological fluids using next-generation sequencing technologies. Front. Genet., 2013, 4, 150.
204. Rao, P.; Benito, E.; Fischer, A. MicroRNAs as biomarkers for CNS disease. Front. Mol. Neurosci., 2013, 6, 39.
205. Malhotra, M.; Tomaro-Duchesneau, C.; Saha, S.; Prakash, S. Intranasal delivery of chitosan-siRNA nanoparticle formulation to the brain. Methods Mol. Bio., 2014, 1141, 233-47.
206. Lu, B.; Nagappan, G.; Guan, X.; Nathan, P. J.; Wren, P. BDNFbased synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat. Rev. Neurosci., 2013, 14(6), 401-16.
207. Krakora, D.; Mulcrone, P.; Meyer, M.; Lewis, C.; Bernau, K.; Gowing, G.; Zimprich, C.; Aebischer, P.; Svendsen, C. N.; Suzuki, M. Synergistic effects of GDNF and VEGF on lifespan and disease progression in a familial ALS rat model. Mol. Ther., 2013, 21(8), 1602-10.
208. Revilla, S.; Ursulet, S.; Alvarez-Lopez, M. J.; Castro-Freire, M.; Perpina, U.; Garcia-Mesa, Y.; Bortolozzi, A.; Gimenez-Llort, L.; Kaliman, P.; Cristofol, R.; Sarkis, C.; Sanfeliu, C. Lenti-GDNF Gene Therapy Protects Against Alzheimer's Disease-Like Neuropathology in 3xTg-AD Mice and MC65 Cells. CNS Neurosci. Ther., 2014.
209. Yurek, D. M.; Fletcher, A. M.; Smith, G. M.; Seroogy, K. B.; Ziady, A. G.; Molter, J.; Kowalczyk, T. H.; Padegimas, L.; Cooper, M. J. Long-term transgene expression in the central nervous system using DNA nanoparticles. Mol. Ther., 2009, 17(4), 641-50.
210. Hernandez-Baltazar, D.; Martinez-Fong, D.; Trudeau, L. E. Optimizing NTS-polyplex as a tool for gene transfer to cultured dopamine neurons. PloS one, 2012, 7(12), e51341.
211. Rowland, L. P.; Shneider, N. A. Amyotrophic lateral sclerosis. N. Engl. J. Med., 2001, 344(22), 1688-700.
212. Pasinelli, P.; Belford, M. E.; Lennon, N.; Bacskai, B. J.; Hyman, B. T.; Trotti, D.; Brown, R. H. Jr. Amyotrophic lateral sclerosisassociated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron, 2004, 43(1), 19-30.
213. DeJesus-Hernandez, M.; Mackenzie, I. R.; Boeve, B. F.; Boxer, A. L.; Baker, M.; Rutherford, N. J.; Nicholson, A. M.; Finch, N. A.; Flynn, H.; Adamson, J.; Kouri, N.; Wojtas, A.; Sengdy, P.; Hsiung, G. Y.; Karydas, A.; Seeley, W. W.; Josephs, K. A.; Coppola, G.; Geschwind, D. H.; Wszolek, Z. K.; Feldman, H.; Knopman, D. S.; Petersen, R. C.; Miller, B. L.; Dickson, D. W.; Boylan, K. B.; Graff-Radford, N. R.; Rademakers, R. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron, 2011, 72(2), 245-56.
214. Renton, A. E.; Majounie, E.; Waite, A.; Simon-Sanchez, J.; Rollinson, S.; Gibbs, J. R.; Schymick, J. C.; Laaksovirta, H.; van Swieten, J. C.; Myllykangas, L.; Kalimo, H.; Paetau, A.; Abramzon, Y.; Remes, A. M.; Kaganovich, A.; Scholz, S. W.; Duckworth, J.; Ding, J.; Harmer, D. W.; Hernandez, D. G.; Johnson, J. O.; Mok, K.; Ryten, M.; Trabzuni, D.; Guerreiro, R. J.; Orrell, R. W.; Neal, J.; Murray, A.; Pearson, J.; Jansen, I. E.; Sondervan, D.; Seelaar, H.; Blake, D.; Young, K.; Halliwell, N.; Callister, J. B.; Toulson, G.; Richardson, A.; Gerhard, A.; Snowden, J.; Mann, D.; Neary, D.; Nalls, M. A.; Peuralinna, T.; Jansson, L.; Isoviita, V. M.; Kaivorinne, A. L.; Holtta-Vuori, M.; Ikonen, E.; Sulkava, R.; Benatar, M.; Wuu, J.; Chio, A.; Restagno, G.; Borghero, G.; Sabatelli, M.; Heckerman, D.; Rogaeva, E.; Zinman, L.; Rothstein, J. D.; Sendtner, M.; Drepper, C.; Eichler, E. E.; Alkan, C.; Abdullaev, Z.; Pack, S. D.; Dutra, A.; Pak, E.; Hardy, J.; Singleton, A.; Williams, N. M.; Heutink, P.; Pickering-Brown, S.; Morris, H. R.; Tienari, P. J.; Traynor, B. J. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron, 2011, 72(2), 257-68.
215. Turner, M. R.; Hardiman, O.; Benatar, M.; Brooks, B. R.; Chio, A.; de Carvalho, M.; Ince, P. G.; Lin, C.; Miller, R. G.; Mitsumoto, H.; Nicholson, G.; Ravits, J.; Shaw, P. J.; Swash, M.; Talbot, K.; Traynor, B. J.; Van den Berg, L. H.; Veldink, J. H.; Vucic, S.; Kiernan, M. C. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol., 2013, 12(3), 310-22.
216. Kim, S. H.; Shi, Y.; Hanson, K. A.; Williams, L. M.; Sakasai, R.; Bowler, M. J.; Tibbetts, R. S. Potentiation of amyotrophic lateral sclerosis (ALS)-associated TDP-43 aggregation by the proteasometargeting factor, ubiquilin 1. J. Biol. Chem., 2009, 284(12), 8083-92.
217. Lagier-Tourenne, C.; Baughn, M.; Rigo, F.; Sun, S.; Liu, P.; Li, H. R.; Jiang, J.; Watt, A. T.; Chun, S.; Katz, M.; Qiu, J.; Sun, Y.; Ling, S. C.; Zhu, Q.; Polymenidou, M.; Drenner, K.; Artates, J. W.; McAlonis-Downes, M.; Markmiller, S.; Hutt, K. R.; Pizzo, D. P.; Cady, J.; Harms, M. B.; Baloh, R. H.; Vandenberg, S. R.; Yeo, G. W.; Fu, X. D.; Bennett, C. F.; Cleveland, D. W.; Ravits, J. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl. Acad. Sci. U. S. A., 2013, 110(47), E4530-9.
218. Falzarano, M. S.; Passarelli, C.; Bassi, E.; Fabris, M.; Perrone, D.; Sabatelli, P.; Maraldi, N. M.; Dona, S.; Selvatici, R.; Bonaldo, P.; Sparnacci, K.; Laus, M.; Braghetta, P.; Rimessi, P.; Ferlini, A. Biodistribution and molecular studies on orally administered nanoparticle-AON complexes encapsulated with alginate aiming at inducing dystrophin rescue in mdx mice. Biomed Res. Int., 2013, 2013, 527418.
219. Klejbor, I.; Stachowiak, E. K.; Bharali, D. J.; Roy, I.; Spodnik, I.; Morys, J.; Bergey, E. J.; Prasad, P. N.; Stachowiak, M. K. ORMOSIL nanoparticles as a non-viral gene delivery vector for modeling polyglutamine induced brain pathology. J. Neurosci. Methods, 2007, 165(2), 230-43.
220. Gunawardena, S. Nanoparticles in the brain: a potential therapeutic system targeted to an early defect observed in many neurodegenerative diseases. Pharm. Res., 2013, 30(10), 2459-74.
221. Godinho, B. M.; Ogier, J. R.; Darcy, R.; O'Driscoll, C. M.; Cryan, J. F. Self-assembling modified beta-cyclodextrin nanoparticles as neuronal siRNA delivery vectors: focus on Huntington's disease. Mol. Pharm., 2013, 10(2), 640-9.
222. S, E. L. A.; Mager, I.; Breakefield, X. O.; Wood, M. J. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov., 2013, 12(5), 347-57.
223. Liu, R.; Liu, J.; Ji, X.; Liu, Y. Synthetic nucleic acids delivered by exosomes: a potential therapeutic for generelated metabolic brain diseases. Metab. Brain Dis., 2013, 28(4), 551-62.
224. Alvarez-Erviti, L.; Seow, Y.; Yin, H.; Betts, C.; Lakhal, S.; Wood, M. J. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nature Biotechnol., 2011, 29(4), 341-5.
225. van den Boorn, J. G.; Schlee, M.; Coch, C.; Hartmann, G. SiRNA delivery with exosome nanoparticles. Nat. Biotechnol., 2011, 29(4), 325-6.
226. Russo, I.; Bubacco, L.; Greggio, E. Exosomes-associated neurodegeneration and progression of Parkinson's disease. Am. J. Neurodegener. Dis., 2012, 1(3), 217-25.
227. Joshi, P.; Turola, E.; Ruiz, A.; Bergami, A.; Libera, D. D.; Benussi, L.; Giussani, P.; Magnani, G.; Comi, G.; Legname, G.; Ghidoni, R.; Furlan, R.; Matteoli, M.; Verderio, C. Microglia convert aggregated amyloid-beta into neurotoxic forms through the shedding of microvesicles. Cell Death Differ., 2014, 21(4), 582-93.
228. Xue, Y.; Wu, J.; Sun, J. Four types of inorganic nanoparticles stimulate the inflammatory reaction in brain microglia and damage neurons in vitro. Toxicol. Lett., 2012, 214(2), 91-8.
229. Wang, Y.; Wang, B.; Zhu, M. T.; Li, M.; Wang, H. J.; Wang, M.; Ouyang, H.; Chai, Z. F.; Feng, W. Y.; Zhao, Y. L. Microglial activation, recruitment and phagocytosis as linked phenomena in ferric oxide nanoparticle exposure. Toxicol. Lett., 2011, 205(1), 26-37.
230. Li, X.; Liu, B.; Li, X. L.; Li, Y. X.; Sun, M. Z.; Chen, D. Y.; Zhao, X.; Feng, X. Z. SiO2 nanoparticles change colour preference and cause Parkinson's-like behaviour in zebrafish. Sci. Rep., 2014, 4, 3810.
231. Raju, H. B.; Hu, Y.; Vedula, A.; Dubovy, S. R.; Goldberg, J. L. Evaluation of magnetic micro- and nanoparticle toxicity to ocular tissues. PloS one, 2011, 6(5), e17452.
232. Sun, Z.; Yathindranath, V.; Worden, M.; Thliveris, J. A.; Chu, S.; Parkinson, F. E.; Hegmann, T.; Miller, D. W. Characterization of cellular uptake and toxicity of aminosilane-coated iron oxide nanoparticles with different charges in central nervous systemrelevant cell culture models. Int. J. Nanomed., 2013, 8, 961-70.
233. Hanahan, D.; Weinberg, R. A. The Hallmarks of Cancer. Cell, 2000, 100(1), 57-70.
234. Luo, J.; Solimini, N. L.; Elledge, S. J. Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction. Cell, 2009, 136(5), 823-837.
235. Ahmad, A.; Kong, D.; Sarkar, S. H.; Wang, Z.; Banerjee, S.; Sarkar, F. H. Inactivation of uPA and its receptor uPAR by 3, 3'-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration. J. Cell. Biochem., 2009, 107(3), 516-27.
236. Albinger-Hegyi, A.; Stoeckli, S. J.; Schmid, S.; Storz, M.; Iotzova, G.; Probst-Hensch, N. M.; Rehrauer, H.; Tinguely, M.; Moch, H.; Hegyi, I. Lysyl oxidase expression is an independent marker of prognosis and a predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC). Int. J. Cancer, 2010, 126(11), 2653-62.
237. Carmeliet, P.; Jain, R. K. Angiogenesis in cancer and other diseases. Nature, 2000, 407(6801), 249-57.
238. Pouyssegur, J.; Dayan, F.; Mazure, N. M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature, 2006, 441(7092), 437-43.
239. Valastyan, S.; Weinberg, R. A. Tumor metastasis: molecular insights and evolving paradigms. Cell, 2011, 147(2), 275-92.
240. Berry, G.; Billingham, M.; Alderman, E.; Richardson, P.; Torti, F.; Lum, B.; Patek, A.; Martin, F. J. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann. Oncol., 1998, 9(7), 711-6.
241. Ewer, M. S.; Martin, F. J.; Henderson, C.; Shapiro, C. L.; Benjamin, R. S.; Gabizon, A. A. Cardiac safety of liposomal anthracyclines. Semin. Oncol., 2004, 31(6 Suppl 13), 161-81.
242. Sharma, G.; Anabousi, S.; Ehrhardt, C.; Ravi Kumar, M. N. Liposomes as targeted drug delivery systems in the treatment of breast cancer. J. Drug Target, 2006, 14(5), 301-10.
243. A service of the U. S. National Institutes of Health-A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer, 2011 (http://clinicaltrials.gov/ct2/show/NCT01300533) (Accessed August 12, 2014).
244. Lynch, T. J.; Bell, D. W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Haserlat, S. M.; Supko, J. G.; Haluska, F. G.; Louis, D. N.; Christiani, D. C.; Settleman, J.; Haber, D. A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 2004, 350(21), 2129-39.
245. Vale, C. L.; Tierney, J.; Bull, S. J.; Symonds, P. R. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst. Rev., 2012, 8, Cd003915.
246. Sharma, A.; Madhunapantula, S. V.; Gowda, R.; Berg, A.; Neves, R. I.; Robertson, G. P. Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E) B-RAF in melanoma. Am. J. Pathol., 2013, 182(4), 1151-62.
247. Forastiere, A. A.; Orringer, M. B.; Perez-Tamayo, C.; Urba, S. G.; Husted, S.; Takasugi, B. J.; Zahurak, M. Concurrent chemotherapy and radiation therapy followed by transhiatal esophagectomy for local-regional cancer of the esophagus. J. Clin. Oncol., 1990, 8(1), 119-27.
248. Moreno Garcia, V.; Basu, B.; Molife, L. R.; Kaye, S. B. Combining antiangiogenics to overcome resistance: rationale and clinical experience. Clin. Cancer Res., 2012, 18(14), 3750-61.
249. Hu, C. M.; Zhang, L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem. Pharmacol., 2012, 83(8), 1104-11.
250. Shapira, A.; Livney, Y. D.; Broxterman, H. J.; Assaraf, Y. G. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist. Updat., 2011, 14(3), 150-63.
251. Sharma, A.; Madhunapantula, S. V.; Robertson, G. P. Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems. Expert Opin. Drug Metab. Toxicol., 2012, 8(1), 47-69.
252. Grodzinski, P.; Silver, M.; Molnar, L. K. Nanotechnology for cancer diagnostics: promises and challenges. Expert Rev. Mol. Diagn., 2006, 6(3), 307-18.
253. McNeil, S. E. Nanotechnology for the biologist. J. Leukoc. Biol., 2005, 78(3), 585-94.
254. Trams, E. G.; Lauter, C. J.; Salem, N. Jr.; Heine, U. Exfoliation of membrane ecto-enzymes in the form of micro-vesicles. Biochim. Biophys. Acta, 1981, 645(1), 63-70.
255. Johnstone, R. M.; Adam, M.; Hammond, J. R.; Orr, L.; Turbide, C., Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J. Biol. Chem., 1987, 262(19), 9412-20.
256. Raposo, G.; Nijman, H. W.; Stoorvogel, W.; Liejendekker, R.; Harding, C. V.; Melief, C. J.; Geuze, H. J. B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med., 1996, 183(3), 1161-72.
257. Zitvogel, L.; Regnault, A.; Lozier, A.; Wolfers, J.; Flament, C.; Tenza, D.; Ricciardi-Castagnoli, P.; Raposo, G.; Amigorena, S. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat. Med., 1998, 4(5), 594-600.
258. Skokos, D.; Le Panse, S.; Villa, I.; Rousselle, J. C.; Peronet, R.; David, B.; Namane, A.; Mecheri, S. Mast cell-dependent B and T lymphocyte activation is mediated by the secretion of immunologically active exosomes. J. Immunol., 2001, 166(2), 868-76.
259. Pant, S.; Hilton, H.; Burczynski, M. E. The multifaceted exosome: biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. Biochem. Pharmacol., 2012, 83(11), 1484-94.
260. Gould, S. J.; Booth, A. M.; Hildreth, J. E. The Trojan exosome hypothesis. Proc. Natl. Acad. Sci. U. S. A., 2003, 100(19), 10592-7.
261. Kowal, J.; Tkach, M.; Thery, C. Biogenesis and secretion of exosomes. Current Opin. Cell Biol., 2014, 29 C, 116-125.
262. Bobrie, A.; Colombo, M.; Krumeich, S.; Raposo, G.; Thery, C. Diverse subpopulations of vesicles secreted by different intracellular mechanisms are present in exosome preparations obtained by differential ultracentrifugation. J. Extracell. Vesicles, 2012, 1.
263. Aalberts, M.; van Dissel-Emiliani, F. M.; van Adrichem, N. P.; van Wijnen, M.; Wauben, M. H.; Stout, T. A.; Stoorvogel, W. Identification of distinct populations of prostasomes that differentially express prostate stem cell antigen, annexin A1, and GLIPR2 in humans. Biol. Reprod., 2012, 86(3), 82.
264. Palma, J.; Yaddanapudi, S. C.; Pigati, L.; Havens, M. A.; Jeong, S.; Weiner, G. A.; Weimer, K. M.; Stern, B.; Hastings, M. L.; Duelli, D. M. MicroRNAs are exported from malignant cells in customized particles. Nucleic Acids Res., 2012, 40(18), 9125-38.
265. Valadi, H.; Ekstrom, K.; Bossios, A.; Sjostrand, M.; Lee, J. J.; Lotvall, J. O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biol., 2007, 9(6), 654-9.
266. Simons, M.; Raposo, G. Exosomes-vesicular carriers for intercellular communication. Current Opin. Cell Biol., 2009, 21(4), 575-81.
267. Sun, D.; Zhuang, X.; Xiang, X.; Liu, Y.; Zhang, S.; Liu, C.; Barnes, S.; Grizzle, W.; Miller, D.; Zhang, H. G. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol. Ther., 2010, 18(9), 1606-14.
268. Waehler, R.; Russell, S. J.; Curiel, D. T. Engineering targeted viral vectors for gene therapy. Nat. Rev. Genet., 2007, 8(8), 573-87.
269. Dobrovolskaia, M. A.; Aggarwal, P.; Hall, J. B.; McNeil, S. E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm., 2008, 5(4), 487-95.
270. Cocucci, E.; Racchetti, G.; Meldolesi, J. Shedding microvesicles: artefacts no more. Trends Cell Biol., 2009, 19(2), 43-51.
271. Hunter, M. P.; Ismail, N.; Zhang, X.; Aguda, B. D.; Lee, E. J.; Yu, L.; Xiao, T.; Schafer, J.; Lee, M. L.; Schmittgen, T. D.; Nana-Sinkam, S. P.; Jarjoura, D.; Marsh, C. B. Detection of microRNA expression in human peripheral blood microvesicles. PloS one, 2008, 3(11), e3694.
272. Taylor, D. D.; Gercel-Taylor, C. MicroRNA signatures of tumorderived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol., 2008, 110(1), 13-21.
273. Pigati, L.; Yaddanapudi, S. C.; Iyengar, R.; Kim, D. J.; Hearn, S. A.; Danforth, D.; Hastings, M. L.; Duelli, D. M. Selective release of microRNA species from normal and malignant mammary epithelial cells. PloS one, 2010, 5(10), e13515.
274. Montecalvo, A.; Larregina, A. T.; Shufesky, W. J.; Stolz, D. B.; Sullivan, M. L.; Karlsson, J. M.; Baty, C. J.; Gibson, G. A.; Erdos, G.; Wang, Z.; Milosevic, J.; Tkacheva, O. A.; Divito, S. J.; Jordan, R.; Lyons-Weiler, J.; Watkins, S. C.; Morelli, A. E. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood, 2012, 119(3), 756-66.
275. Graner, M. W.; Alzate, O.; Dechkovskaia, A. M.; Keene, J. D.; Sampson, J. H.; Mitchell, D. A.; Bigner, D. D. Proteomic and immunologic analyses of brain tumor exosomes. FASEB J., 2009, 23(5), 1541-57.
276. Al-Nedawi, K.; Meehan, B.; Micallef, J.; Lhotak, V.; May, L.; Guha, A.; Rak, J. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nature Cell Biol., 2008, 10(5), 619-24.
277. Skog, J.; Wurdinger, T.; van Rijn, S.; Meijer, D. H.; Gainche, L.; Sena-Esteves, M.; Curry, W. T. Jr.; Carter, B. S.; Krichevsky, A. M.; Breakefield, X. O. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nature Cell Biol., 2008, 10(12), 1470-6.
278. Allen, T. M. Ligand-targeted therapeutics in anticancer therapy. Nature reviews. Cancer, 2002, 2(10), 750-63.
279. Langer, R. Drug delivery and targeting. Nature, 1998, 392(6679 Suppl), 5-10.
280. Bourzac, K. Nanotechnology: Carrying drugs. Nature, 2012, 491(7425), S58-S60.
281. Bondi, M. L.; Craparo, E. F.; Giammona, G.; Drago, F. Braintargeted solid lipid nanoparticles containing riluzole: preparation, characterization and biodistribution. Nanomedicine, 2010, 5(1), 25-32.
282. Kang, K. W.; Chun, M.-K.; Kim, O.; Subedi, R. K.; Ahn, S.-G.; Yoon, J.-H.; Choi, H.-K. Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomedicine, 2010, 6(2), 210-213.
283. Han, Y.; Zhang, P.; Chen, Y.; Sun, J.; Kong, F. Co-delivery of plasmid DNA and doxorubicin by solid lipid nanoparticles for lung cancer therapy. Int. J. Mol. Med., 2014, 34(1), 191-6.
284. Yusuf, M.; Khan, M.; Khan, R. A.; Ahmed, B. Preparation, characterization, in vivo and biochemical evaluation of brain targeted Piperine solid lipid nanoparticles in an experimentally induced Alzheimer's disease model. J. Drug Target, 2012.
285. Sandhir, R.; Yadav, A.; Mehrotra, A.; Sunkaria, A.; Singh, A.; Sharma, S. Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington's disease. Neuro Molecular Med., 2014, 16(1), 106-18.
286. Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol., 2007, 2(12), 751-60.
287. Pastan, I.; Hassan, R.; Fitzgerald, D. J.; Kreitman, R. J. Immunotoxin therapy of cancer. Nat. Rev. Cancer, 2006, 6(7), 559-65.
288. Shi, J.; Xiao, Z.; Kamaly, N.; Farokhzad, O. C. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc. Chem. Res., 2011, 44(10), 1123-34.
289. Mrozek, E.; Rhoades, C. A.; Allen, J.; Hade, E. M.; Shapiro, C. L. Phase I trial of liposomal encapsulated doxorubicin (Myocet; D-99) and weekly docetaxel in advanced breast cancer patients. Ann. Oncol., 2005, 16(7), 1087-93.
290. Airoldi, C.; Mourtas, S.; Cardona, F.; Zona, C.; Sironi, E.; D'Orazio, G.; Markoutsa, E.; Nicotra, F.; Antimisiaris, S. G.; La Ferla, B. Nanoliposomes presenting on surface a cis-glycofused benzopyran compound display binding affinity and aggregation inhibition ability towards Amyloid beta1-42 peptide. Eur. J. Med. Chem., 2014, 85 c, 43-50.
291. Iwasaki, Y.; Maie, H.; Akiyoshi, K. Cell-specific delivery of polymeric nanoparticles to carbohydrate-tagging cells. Biomacromolecules, 2007, 8(10), 3162-8.
292. Ngwa, W.; Kumar, R.; Sridhar, S.; Korideck, H.; Zygmanski, P.; Cormack, R. A.; Berbeco, R.; Makrigiorgos, G. M. Targeted radiotherapy with gold nanoparticles: current status and future perspectives. Nanomedicine, 2014, 9(7), 1063-82.
293. von Maltzahn, G.; Park, J. H.; Lin, K. Y.; Singh, N.; Schwoppe, C.; Mesters, R.; Berdel, W. E.; Ruoslahti, E.; Sailor, M. J.; Bhatia, S. N. Nanoparticles that communicate in vivo to amplify tumour targeting. Nat. Mater., 2011, 10(7), 545-52.
294. Cao-Milan, R.; Liz-Marzan, L. M. Gold nanoparticle conjugates: recent advances toward clinical applications. Expert Opin. Drug Deliv., 2014, 11(5), 741-52.
295. Kumar, D.; Saini, N.; Jain, N.; Sareen, R.; Pandit, V. Gold nanoparticles: an era in bionanotechnology. Expert Opin. Drug Deliv., 2013, 10(3), 397-409.
296. Kim, J. Y.; Choi, W. I.; Kim, Y. H.; Tae, G. Brain-targeted delivery of protein using chitosan- and RVG peptide-conjugated, pluronic-based nano-carrier. Biomaterials, 2013, 34(4), 1170-8.
297. Ren, J.; Shen, S.; Wang, D.; Xi, Z.; Guo, L.; Pang, Z.; Qian, Y.; Sun, X.; Jiang, X. The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials, 2012, 33(11), 3324-33.
298. Liu, D.; Wang, L.; Wang, Z.; Cuschieri, A. Magnetoporation and magnetolysis of cancer cells via carbon nanotubes induced by rotating magnetic fields. Nano Lett., 2012, 12(10), 5117-21.
299. Mundra, R. V.; Wu, X.; Sauer, J.; Dordick, J. S.; Kane, R. S. Nanotubes in biological applications. Curr. Opin. Biotechnol., 2014, 28 c, 25-32.
300. Liu, Z.; Fan, A. C.; Rakhra, K.; Sherlock, S.; Goodwin, A.; Chen, X.; Yang, Q.; Felsher, D. W.; Dai, H. Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy. Angew. Chem., 2009, 48(41), 7668-72.
301. Lay, C. L.; Liu, H. Q.; Tan, H. R.; Liu, Y. Delivery of paclitaxel by physically loading onto poly (ethylene glycol) (PEG)-graft-carbon nanotubes for potent cancer therapeutics. Nanotechnology, 2010, 21(6), 065101.
302. McCarthy, J. M.; Appelhans, D.; Tatzelt, J.; Rogers, M. S. Nanomedicine for prion disease treatment: new insights into the role of dendrimers. Prion, 2013, 7(3), 198-202.
303. Liu, S.; Guo, Y.; Huang, R.; Li, J.; Huang, S.; Kuang, Y.; Han, L.; Jiang, C. Gene and doxorubicin co-delivery system for targeting therapy of glioma. Biomaterials, 2012, 33(19), 4907-16.
304. Li, Y.; He, H.; Jia, X.; Lu, W. L.; Lou, J.; Wei, Y. A dual-targeting nanocarrier based on poly (amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials, 2012, 33(15), 3899-908.
305. Wu, G.; Yang, W.; Barth, R. F.; Kawabata, S.; Swindall, M.; Bandyopadhyaya, A. K.; Tjarks, W.; Khorsandi, B.; Blue, T. E.; Ferketich, A. K.; Yang, M.; Christoforidis, G. A.; Sferra, T. J.; Binns, P. J.; Riley, K. J.; Ciesielski, M. J.; Fenstermaker, R. A. Molecular targeting and treatment of an epidermal growth factor receptorpositive glioma using boronated cetuximab. Clin. Cancer Res., 2007, 13(4), 1260-8.
306. Machtoub, L.; Bataveljic, D.; Andjus, P. R. Molecular imaging of brain lipid environment of lymphocytes in amyotrophic lateral sclerosis using magnetic resonance imaging and SECARS microscopy. Physiol. Res., 2011, 60 Suppl 1, S121-7.
307. Bataveljic, D.; Stamenkovic, S.; Bacic, G.; Andjus, P. R. Imaging cellular markers of neuroinflammation in the brain of the rat model of amyotrophic lateral sclerosis. Acta Physiol. Hung., 2011, 98(1), 27-31.
308. Orel, V.; Shevchenko, A.; Romanov, A.; Tselepi, M.; Mitrelias, T.; Barnes, C. H.; Burlaka, A.; Lukin, S.; Shchepotin, I. Magnetic properties and antitumor effect of nanocomplexes of iron oxide and doxorubicin. Nanomedicine, 2014.
309. Cimini, A.; D'Angelo, B.; Das, S.; Gentile, R.; Benedetti, E.; Singh, V.; Monaco, A. M.; Santucci, S.; Seal, S. Antibody-conjugated PEGylated cerium oxide nanoparticles for specific targeting of Abeta aggregates modulate neuronal survival pathways. Acta biomaterialia, 2012, 8(6), 2056-67.
310. Singh, V.; Singh, S.; Das, S.; Kumar, A.; Self, W. T.; Seal, S. A facile synthesis of PLGA encapsulated cerium oxide nanoparticles: release kinetics and biological activity. Nanoscale, 2012, 4(8), 2597-605.
311. Pang, J.; Zhao, L.; Zhang, L.; Li, Z.; Luan, Y. Folate-conjugated hybrid SBA-15 particles for targeted anticancer drug delivery. J. Colloid Interface Sci., 2013, 395, 31-9.
312. Kim, D. H.; Rozhkova, E. A.; Ulasov, I. V.; Bader, S. D.; Rajh, T.; Lesniak, M. S.; Novosad, V. Biofunctionalized magnetic-vortex microdiscs for targeted cancer-cell destruction. Nat. Mater., 2010, 9(2), 165-71.
313. Klichko, Y.; Liong, M.; Choi, E.; Angelos, S.; Nel, A. E.; Stoddart, J. F.; Tamanoi, F.; Zink, J. I. Mesostructured Silica for Optical Functionality, Nanomachines, and Drug Delivery. J. Am. Ceram. Soc., 2009, 92(s1), s2-s10.
314. Fan, J.; Fang, G.; Wang, X.; Zeng, F.; Xiang, Y.; Wu, S. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles. Nanotechnology, 2011, 22(45), 455102.
315. Kratz, F.; Muller, I. A.; Ryppa, C.; Warnecke, A. Prodrug strategies in anticancer chemotherapy. ChemMedChem, 2008, 3(1), 20-53.
316. Arnfast, L.; Madsen, C. G.; Jorgensen, L.; Baldursdottir, S. Design and processing of nanogels as delivery systems for peptides and proteins. Ther. Deliv., 2014, 5(6), 691-708.
317. Yallapu, M. M.; Jaggi, M.; Chauhan, S. C. Design and engineering of nanogels for cancer treatment. Drug Discov. Today, 2011, 16(9-10), 457-63.